RESUMEN
One-third of people with schizophrenia have elevated levels of anti-gliadin antibodies (AGA IgG). A 5-week randomized double-blind pilot study was performed in 2014-2017 in an inpatient setting to test the effect of a gluten-free diet (GFD) on participants with schizophrenia or schizoaffective disorder who also had elevated AGA IgG (≥ 20 U) but were negative for celiac disease. This earlier pilot study reported that the GFD-group showed improved gastrointestinal and psychiatric symptoms, and also improvements in TNF-α and the inflammatory cytokine IL-23. Here, we performed measurements of these banked plasma samples to detect levels of oxidative stress (OxSt) using a recently developed iridium (Ir)-reducing capacity assay. Triplicate measurements of these samples showed an Intraclass Correlation Coefficient of 0.84 which indicates good reproducibility. Further, a comparison of the OxSt measurements at the baseline and 5-week end-point for this small sample size shows that the GFD-group (N = 7) had lowered OxSt levels compared to the gluten-containing diet group (GCD; N = 9; p = 0.05). Finally, we showed that improvements in OxSt over these 5 weeks were correlated to improvements in gastrointestinal (r = +0.64, p = 0.0073) and psychiatric (r = +0.52, p = 0.039) symptoms. Also, we showed a possible association between the decrease in OxSt and the lowered levels of IL-23 (r = +0.44, p = 0.087), although without statistical significance. Thus, the Ir-reducing capacity assay provides a simple, objective measure of OxSt with the results providing further evidence that inflammation, redox dysregulation and OxSt may mediate interactions between the gut and brain.
Asunto(s)
Dieta Sin Gluten , Estrés Oxidativo , Esquizofrenia , Humanos , Esquizofrenia/dietoterapia , Esquizofrenia/sangre , Proyectos Piloto , Estrés Oxidativo/fisiología , Masculino , Adulto , Femenino , Persona de Mediana Edad , Método Doble Ciego , Trastornos Psicóticos/dietoterapia , Trastornos Psicóticos/sangre , Trastornos Psicóticos/inmunología , Gliadina/inmunologíaRESUMEN
Omega-3-polyunsaturated-fatty-acids were suggested against cognitive dysfunctions and conversion to psychosis. However, a recent multicenter trial found no effect in reducing conversion rates in individuals at risk of developing schizophrenia. Patients' genetic heterogeneity and the timing of treatment might influence omega-3 efficacy. Here, we addressed the impact of omega-3 early treatment in both mice and human subjects with a 22q11.2 genetic hemi-deletion (22q11DS), characterized by cognitive dysfunctions and high penetrance of schizophrenia. We first tested the behavioural and cognitive consequences of adolescent exposure to normal or omega-3-enriched diets in wild-type and 22q11DS (LgDel/+) mice. We then contrasted mouse data with those gathered from sixty-two patients with 22q11DS exposed to a normal diet or supplemented with omega-3 during pre-adolescence/adolescence. Adolescent omega-3 exposure had no effects in wild-type mice. However, this treatment ameliorated distractibility deficits revealed in LgDel/+ mice by the Five Choice Serial Reaction Time Task (5CSRTT). The omega-3 improvement in LgDel/+ mice was selective, as no other generalized cognitive and non-cognitive effects were evident. Similarly, omega-3-exposed 22q11DS patients showed long-lasting improvements on distractibility as revealed by the continuous performance test (CPT). Moreover, omega-3-exposed 22q11DS patients showed less risk of developing an Ultra High Risk status and lower conversion rate to psychosis. Our convergent mouse-human findings represent a first analysis on the effects of omega-3 early treatment in 22q11DS. The beneficial effects in attentional control and transition to psychosis could support the early use of omega-3 supplementation in the 22q11DS population.
Asunto(s)
Síndrome de DiGeorge/dietoterapia , Síndrome de DiGeorge/psicología , Suplementos Dietéticos , Ácidos Grasos Omega-3/administración & dosificación , Trastornos Psicóticos/dietoterapia , Trastornos Psicóticos/psicología , Adolescente , Adulto , Animales , Atención/efectos de los fármacos , Atención/fisiología , Niño , Estudios de Cohortes , Síndrome de DiGeorge/genética , Femenino , Estudios de Seguimiento , Humanos , Masculino , Pruebas de Estado Mental y Demencia , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Trastornos Psicóticos/genética , Resultado del Tratamiento , Adulto JovenRESUMEN
INTRODUCTION: Schizophrenia spectrum disorders (SSD) represent a cluster of severe mental illnesses. Diet has been identified as a modifiable risk factor and opportunity for intervention in many physical illnesses and more recently in mental illnesses such as unipolar depression; however, no dietary guidelines exist for patients with SSD. OBJECTIVE: This review sought to systematically scope the existing literature in order to identify nutritional interventions for the prevention or treatment of mental health symptoms in SSD as well as gaps and opportunities for further research. METHODS: This review followed established methodological approaches for scoping reviews including an extensive a priori search strategy and duplicate screening. Because of the large volume of results, an online program (Abstrackr) was used for screening and tagging. Data were extracted based on the dietary constituents and analyzed. RESULTS: Of 55,330 results identified by the search, 822 studies met the criteria for inclusion. Observational evidence shows a connection between the presence of psychotic disorders and poorer quality dietary patterns, higher intake of refined carbohydrates and total fat, and lower intake or levels of fibre, ω-3 and ω-6 fatty acids, vegetables, fruit, and certain vitamins and minerals (vitamin B12 and B6, folate, vitamin C, zinc, and selenium). Evidence illustrates a role of food allergy and sensitivity as well as microbiome composition and specific phytonutrients (such as L-theanine, sulforaphane, and resveratrol). Experimental studies have demonstrated benefit using healthy diet patterns and specific vitamins and minerals (vitamin B12 and B6, folate, and zinc) and amino acids (serine, lysine, glycine, and tryptophan). DISCUSSION: Overall, these findings were consistent with many other bodies of knowledge about healthy dietary patterns. Many limitations exist related to the design of the individual studies and the ability to extrapolate the results of studies using dietary supplements to dietary interventions (food). Dietary recommendations are presented as well as recommendations for further research including more prospective observational studies and intervention studies that modify diet constituents or entire dietary patterns with statistical power to detect mental health outcomes.
Asunto(s)
Dieta , Fenómenos Fisiológicos de la Nutrición , Trastornos Psicóticos , Esquizofrenia , Humanos , Trastornos Psicóticos/dietoterapia , Trastornos Psicóticos/etiología , Trastornos Psicóticos/prevención & control , Esquizofrenia/dietoterapia , Esquizofrenia/etiología , Esquizofrenia/prevención & controlRESUMEN
Background: Approximately one-third of people with schizophrenia have elevated levels of anti-gliadin antibodies of the immunoglobulin G type (AGA IgG) a higher rate than seen in healthy controls. We performed the first double-blind clinical trial of gluten-free versus gluten-containing diets in a subset of patients with schizophrenia who were positive for AGA IgG. Methods: In this pilot feasibility study, 16 participants with schizophrenia or schizoaffective disorder who had elevated AGA IgG (≥ 20 U) but were negative for celiac disease were admitted to an inpatient unit for a 5-week trial. All participants received standardized gluten-free meals and were randomized in a double-blind fashion to receive a shake containing 10 g of gluten flour or 10 g of rice flour each day. Participants were rated for psychiatric, cognitive and gastrointestinal symptoms at baseline and endpoint. Results: Of the 16 participants, 14 completed the 5-week trial (2 discontinued early for administrative reasons). Compared with participants on the gluten-containing diet, participants on the gluten-free diet showed improvement on the Clinical Global Impressions scale (Cohen d = 0.75) and in negative symptoms (Cohen d = 0.53). We noted no improvement in positive or global cognitive symptoms, but did observe an improvement in attention favouring the gluten-free diet (Cohen d = 0.60). Robust improvements in gastrointestinal adverse effects occurred in the gluten-free group relative to the glutencontaining group. Adverse effects were similar between groups. Limitations: This study was limited by its small sample size; larger studies are needed. Conclusion: This feasibility study suggests that removal of gluten from the diet is associated with improvement in psychiatric and gastrointestinal symptoms in people with schizophrenia or schizoaffective disorder.
Asunto(s)
Gliadina/inmunología , Trastornos Psicóticos/dietoterapia , Trastornos Psicóticos/inmunología , Esquizofrenia/dietoterapia , Esquizofrenia/inmunología , Adulto , Anticuerpos/inmunología , Dieta Sin Gluten , Método Doble Ciego , Estudios de Factibilidad , Femenino , Humanos , Inmunoglobulina G/inmunología , Masculino , Persona de Mediana Edad , Evaluación de Resultado en la Atención de Salud , Proyectos PilotoRESUMEN
AIM: Attenuated psychotic symptoms (APSs) have been the primary emphasis in youth at clinical high risk (CHR) for psychosis for assessing symptomology and determining subsequent transition to a psychotic disorder. Previous reviews primarily focused on the efficacy of cognitive behavioural therapy (CBT) on APS; however, a comprehensive assessment of other interventions to date is lacking. Therefore, we conducted a systematic review and meta-analysis of all intervention studies examining APS in CHR youth. METHOD: The authors searched Embase, CINAHL, PsycINFO, Medline and EBM from inception to May 2017. Studies were selected if they included any intervention that reported follow-up APS in youth at CHR. Interventions were evaluated and stratified by time using both pairwise and network meta-analyses (NMAs). Due to the differences in APS scales, effect sizes were calculated as Hedges g and reported as the standardized mean difference (SMD). RESULTS: Forty-one studies met our inclusion criteria. In pairwise meta-analyses, CBT was associated with a trend towards reduction in APS compared to controls at 12-months. In the NMA, integrated psychological therapy, CBT, supportive therapy, family therapy, needs-based interventions, omega-3, risperidone plus CBT and olanzapine were not significantly more effective at reducing APS at 6 and 12 months relative to any other intervention. CONCLUSIONS: CBT demonstrated a slight trend at reducing APS at long-term follow-up compared to controls. No interventions were significantly more effective at reducing APS compared to all other interventions in the NMA. [Correction added on 4 June 2018, after first online publication: Some parts of the Abstract section particularly 'Results' and 'Conclusions' have been corrected.].
Asunto(s)
Antipsicóticos/uso terapéutico , Ácidos Grasos Omega-3/uso terapéutico , Psicoterapia , Trastornos Psicóticos/terapia , Humanos , Trastornos Psicóticos/dietoterapia , Trastornos Psicóticos/tratamiento farmacológicoRESUMEN
AIM: The effects of nutrient-based treatments, including adjunctive vitamin or antioxidant supplementation, have been explored extensively in long-term schizophrenia. However, no systematic evaluation of trials in "first-episode psychosis" (FEP) has been conducted, despite the potential benefits of using these treatments during the early stages of illness. Therefore, we aimed to review all studies examining efficacy, tolerability and the biological mechanisms of action, of nutrient supplementation in FEP. METHODS: A systematic review of electronic databases was conducted from inception to July 2017. All information on feasibility, clinical outcomes and mechanistic findings from nutrient supplementation clinical trials was extracted and systematically synthesized. RESULTS: Eleven studies with a total of 451 patients with FEP (from 8 independent randomized controlled trials) were eligible for inclusion. Six studies examined omega-3 fatty acids, with inconsistent effects on psychiatric symptoms. However, mechanistic studies found significant improvements in hippocampal neuronal health and brain glutathione. Antioxidants "n-acetyl cysteine" (n = 1) and vitamin C (n = 2) also improved oxidative status in FEP, which was associated with reduced psychiatric symptoms. No benefits were found for vitamin E (n = 1). Finally, one study trialling the amino acid taurine, showed significant improvements in positive symptoms and psychosocial functioning. CONCLUSION: There is preliminary evidence that taurine improves outcomes in FEP, whereas effects of omega-3 and antioxidant vitamins/amino-acids are inconsistent; perhaps mainly benefitting patients with high levels of oxidative stress. Future studies should evaluate multifaceted dietary and supplementation interventions in FEP; targeting-specific nutritional deficits and the range of aberrant biological processes implicated in the disorder.
Asunto(s)
Suplementos Dietéticos/efectos adversos , Nutrientes/efectos adversos , Nutrientes/uso terapéutico , Trastornos Psicóticos/dietoterapia , Quimioterapia Combinada/métodos , Humanos , Trastornos Psicóticos/tratamiento farmacológicoRESUMEN
AIM: The aim of this analysis was to assess changes in lipid parameters, specifically in triglyceride (TG) levels, in a population at ultra-high risk (UHR) for psychosis treated with ω-3 polyunsaturated fatty acids (PUFAs) versus placebo. METHODS: Data were derived from a randomized, double-blind, placebo-controlled trial conducted at an early psychosis unit. Eighty-one individuals, aged 13-25 years, at UHR for psychosis participated in a 12-week intervention trial of 1.2 g/day of ω-3 PUFAs (n = 41) versus placebo (n = 40). Lipid and C-reactive protein levels were collected at baseline and after 12 weeks. RESULTS: Between-group comparisons showed no significant difference in TG levels after the intervention. However, in individuals with baseline TG levels above 150 mg dL-1 there was a significant mean TG reduction of 67.29 (SD 42.54; P = 0.006) in the ω-3 group (n = 7). CONCLUSION: In this sample of UHR individuals, a 12-week intervention with ω-3 PUFAs was effective in reducing previously elevated TG levels. This might introduce the possibility of altering the lipid profile and thus the risk of cardiovascular morbidity of UHR individuals.
Asunto(s)
Ácidos Grasos Omega-3/farmacología , Síntomas Prodrómicos , Trastornos Psicóticos/sangre , Triglicéridos/sangre , Adolescente , Adulto , Proteína C-Reactiva/metabolismo , Método Doble Ciego , Ácidos Grasos Omega-3/uso terapéutico , Femenino , Humanos , Masculino , Trastornos Psicóticos/diagnóstico , Trastornos Psicóticos/dietoterapia , Trastornos Psicóticos/metabolismo , Adulto JovenRESUMEN
BACKGROUND: Populations exposed to humanitarian emergencies are particularly vulnerable to mental health problems, including new onset, relapse and deterioration of psychotic disorders. Inadequate care for this group may lead to human rights abuses and even premature death. The WHO Mental Health Gap Action Programme Intervention Guide (mhGAP-IG), and its adaptation for humanitarian settings (mhGAP-HIG), provides guidance for management of mental health conditions by non-specialised healthcare professionals. However, the pharmacological treatment of people with non-affective psychosis who do not improve with mhGAP first-line antipsychotic treatments is not addressed. In order to fill this gap, UNHCR has formulated specific guidance on the second-line pharmacological treatment of non-affective psychosis in humanitarian, non-specialised settings. METHODS: Following the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology, a group of international experts performed an extensive search and retrieval of evidence on the basis of four scoping questions. Available data were critically appraised and summarised. Clinical guidance was produced by integrating this evidence base with context-related feasibility issues, preferences, values and resource-use considerations. RESULTS: When first-line treatments recommended by mhGAP (namely haloperidol and chlorpromazine) are not effective, no other first-generation antipsychotics are likely to provide clinically meaningful improvements. Risperidone or olanzapine may represent beneficial second-line options. However, if these second-line medications do not produce clinically significant beneficial effects, there are two possibilities. First, to switch to the alternative (olanzapine to risperidone or vice versa) or, second, to consider clozapine, provided that specialist supervision and regular laboratory monitoring are available in the long term. If clinically relevant depressive, cognitive or negative symptoms occur, the use of a selective serotonin reuptake inhibitor may be considered in addition or as an alternative to standard psychological interventions. CONCLUSIONS: Adapting scientific evidence into practical guidance for non-specialised health workers in humanitarian settings was challenging due to the paucity of relevant evidence as well as the imprecision and inconsistency of results between studies. Pragmatic outcome evaluation studies from low-resource contexts are urgently needed. Nonetheless, the UNHCR clinical guidance is based on best available evidence and can help to address the compelling issue of undertreated, non-affective psychosis in humanitarian settings.
Asunto(s)
Antipsicóticos/uso terapéutico , Trastornos Psicóticos/tratamiento farmacológico , Sistemas de Socorro , Benzodiazepinas/uso terapéutico , Guías como Asunto , Humanos , Olanzapina , Trastornos Psicóticos/diagnóstico , Trastornos Psicóticos/dietoterapia , Risperidona/uso terapéutico , Naciones UnidasRESUMEN
BACKGROUND: While accumulating evidence suggests that vitamin D deficiency may be involved in the risk to develop schizophrenia and its outcome, there are no studies on vitamin D supplementation in this context. We sought to assess the effect of vitamin D supplementation on psychiatric, cognitive and metabolic parameters in chronic clozapine-treated schizophrenia patients. METHODS: This eight-week, randomized, double-blind, placebo-controlled clinical trial, recruited schizophrenia patients who had been maintained on clozapine treatment for at least 18weeks and had low levels of vitamin D (<75nmol/l) and total PANSS scores >70 (to ascertain the presence of residual symptoms). Patients were randomly allocated to either weekly oral drops of vitamin D (14,000IU) or placebo and subsequently assessed at two-week intervals for psychosis severity, mood, cognition and metabolic profile. RESULTS: Twenty four patients were randomly assigned to vitamin D (aged 39.4±9.6years, 75% males) and the other 23 patients to the placebo arm (aged 42.5±11.2years, 60.9% males). After eight weeks, the vitamin D group exhibited a significant increase in vitamin D levels (31.4 vs -0.4nmol/l, p<0.0001). There was no significant effect of vitamin D on psychotic, depressive or metabolic parameters. However, in the vitamin D group, there was a trend towards improved cognition (effect size=0.17, significance lost following Bonferroni correction). CONCLUSIONS: Vitamin D supplementation was associated with a trend towards improved cognition, but did not affect psychosis, mood or metabolic status. It is possible that the robust decrease in the PANSS scores in both groups may have obscured an effect of vitamin D supplementation.
Asunto(s)
Clozapina/administración & dosificación , Suplementos Dietéticos , Trastornos Psicóticos/tratamiento farmacológico , Esquizofrenia/tratamiento farmacológico , Adulto , Antipsicóticos/administración & dosificación , Antipsicóticos/efectos adversos , Clozapina/efectos adversos , Cognición/efectos de los fármacos , Cognición/fisiología , Método Doble Ciego , Femenino , Humanos , Masculino , Síndrome Metabólico/sangre , Síndrome Metabólico/dietoterapia , Síndrome Metabólico/tratamiento farmacológico , Síndrome Metabólico/patología , Persona de Mediana Edad , Trastornos Psicóticos/sangre , Trastornos Psicóticos/dietoterapia , Trastornos Psicóticos/patología , Esquizofrenia/sangre , Esquizofrenia/dietoterapia , Esquizofrenia/patología , Vitamina D/administración & dosificación , Vitamina D/sangreRESUMEN
There is growing interest about the potential of diet and nutrients to improve the mental health of the population and for the treatment of psychiatric disorders. In the case of schizophrenia, the limitations of antipsychotic drugs to achieve adequate rates of clinical remission and functional recovery have promoted the search for complementary approaches. This narrative review approaches the dietary patterns and interventions in schizophrenia, efficacy of specific nutrients and therapeutic modulation of the gut microflora by probiotics. As a whole, schizophrenia patients follow a low-quality diet and are exposed to deficiencies in various nutrients that are essential for brain functioning. Although clinical trials with nutritional supplements are still limited and have inconsistent results, specific nutrients, as Omega-3, vitamin D and Group B vitamins can be useful as complementary strategies in the treatment of schizophrenia. It is hoped that the initiation of personalized medicine strategies, such as stratification and using a clinical staging approach, will make it possible to identify the subgroups of patients who can obtain maximum benefit from dietary and nutritional interventions.
Asunto(s)
Suplementos Dietéticos , Trastornos Psicóticos/dietoterapia , Ácidos Grasos Omega-3/uso terapéutico , Microbioma Gastrointestinal , Humanos , Esquizofrenia/dietoterapia , Vitaminas/uso terapéuticoRESUMEN
OBJECTIVE: The objective of the study was to investigate whether a combined intervention composed of early detection plus integrated care (EDIC) enhances outcomes in patients with early psychosis compared to standard care (SC). METHODS: ACCESS III is a prospective non-randomized historical control design 1-year study examining the efficacy of EDIC (n = 120) vs. SC (n = 105) in patients aged 12-29 years. Primary outcome was the rate of ≥6 months combined symptomatic and functional remission. Additional outcomes comprised the reduction of DUP and course of psychopathology, functioning, quality of life, and satisfaction with care. RESULTS: In observed cases, 48.9% in the EDIC and 15.2% in the SC group reached the primary endpoint. Remission was predicted by EDIC (OR = 6.8, CI: 3.15-14.53, P < 0.001); younger age predicted non-remission (OR = 1.1, CI: 1.01-1.19, P = 0.038). Linear regressions indicated a reduction of DUP in EDIC (P < 0.001), but not in SC (P = 0.41). MMRMs showed significantly larger improvements in PANSS positive (P < 0.001) and GAF (P < 0.01) scores in EDIC vs. SC, and in EDIC over time in CGI-Severity (P < 0.001) and numerically in Q-LES-Q-18 (P = 0.052). CONCLUSIONS: EDIC lead to significantly higher proportions of patients achieving combined remission. Moderating variables included a reduction of DUP and EDIC, offering psychotherapeutic interventions.
Asunto(s)
Intervención Médica Temprana/estadística & datos numéricos , Atención al Paciente/estadística & datos numéricos , Trastornos Psicóticos/dietoterapia , Adolescente , Adulto , Diagnóstico Precoz , Femenino , Estudios de Seguimiento , Humanos , Modelos Lineales , Estudios Prospectivos , Trastornos Psicóticos/epidemiología , Adulto JovenRESUMEN
Alterations of immune function have been reported in ultra-high risk (UHR) for psychosis patients causing expectations in terms of predictive meaningfulness and benefits of anti-inflammatory agents. According to a RCT in UHR-patients supplementation of omega-3 polyunsaturated fatty acids (PUFA) was effective in reducing transition to psychosis risk and to improve symptomatology. Based on preclinical findings, we now investigated state marker properties of and the influence of PUFA on immune markers in a RCT (clinical trials.gov Identifier: NCT00396643). In a longitudinal design we measured plasma levels of the pro-inflammatory interleukin 6 (IL-6), the soluble alpha (Tac) subunit of the interleukin 2 receptor (sIL-2r), and the circulating soluble form of the intercellular adhesion molecule one (sICAM-1), in 79 help-seeking UHR individuals (13-25years of age). Using linear mixed model (LMM) analysis, we investigated the effects of 12weeks supplementation of either 1.2g/d PUFA (n=38) or Placebo (n=41). At baseline, inflammatory markers were not altered in patients who later suffered transition to psychosis within one year (n=12; 11 PUFA-group, 1 PL-group). IL-6 was weakly inverse associated with omega-6 PUFA, and highly increased in nicotine users. In univariate tests of the LMM omega-3 PUFA caused a significant increase of sICAM-1 (p=0.022). PUFA did not significantly influence IL-6 or sIL-2r. The enhancement of sICAM-1 in the PUFA condition is suggestive for supportive effects on vascular immune response and immediate Th1 helper cell mediated immune answer, which was found disturbed in manifest schizophrenia, e.g. by facilitating the leukocyte adhesion and migration across the endothelium.
Asunto(s)
Suplementos Dietéticos , Ácidos Grasos Omega-3/administración & dosificación , Trastornos Psicóticos/dietoterapia , Trastornos Psicóticos/inmunología , Adolescente , Adulto , Biomarcadores/sangre , Estudios Transversales , Progresión de la Enfermedad , Método Doble Ciego , Femenino , Humanos , Molécula 1 de Adhesión Intercelular/sangre , Subunidad alfa del Receptor de Interleucina-2/sangre , Interleucina-6/sangre , Masculino , Aceptación de la Atención de Salud , Síntomas Prodrómicos , Trastornos Psicóticos/sangre , Trastornos Psicóticos/prevención & control , Riesgo , Resultado del Tratamiento , Adulto JovenRESUMEN
Existe un interés creciente en el potencial de la dieta y los nutrientes para mejorar la salud mental de la población y para el tratamiento de los trastornos psiquiátricos. En el caso de la esquizofrenia, las limitaciones de los fármacos antipsicóticos para lograr tasas adecuadas de remisión clínica y recuperación funcional han impulsado la búsqueda de abordajes complementarios. En esta revisión narrativa se abordan los patrones dietéticos y las intervenciones dietéticas en esquizofrenia, la eficacia de nutrientes específicos y la modulación terapéutica de la microflora intestinal mediante probióticos. En conjunto, los pacientes con esquizofrenia siguen dietas de pobre calidad y están expuestos a deficiencias en varios nutrientes esenciales para el funcionamiento cerebral. Aunque los ensayos clínicos con suplementos nutricionales son aún escasos y con resultados inconsistentes, nutrientes específicos, como los Omega-3, la vitamina D y las vitaminas del grupo B, pueden ser útiles como estrategias complementarias en el tratamiento de la esquizofrenia. Se espera que la puesta en marcha de estrategias de medicina personalizada, como la estratificación y una perspectiva de estadiaje clínico, posibilite identificar a los subgupos de pacientes que puedan obtener el máximo beneficio de las intervenciones diéteticas y nutricionales (AU)
There is growing interest about the potential of diet and nutrients to improve the mental health of the population and for the treatment of psychiatric disorders. In the case of schizophrenia, the limitations of antipsychotic drugs to achieve adequate rates of clinical remission and functional recovery have promoted the search for complementary approaches. This narrative review approaches the dietary patterns and interventions in schizophrenia, efficacy of specific nutrients and therapeutic modulation of the gut microflora by probiotics. As a whole, schizophrenia patients follow a low-quality diet and are exposed to deficiencies in various nutrients that are essential for brain functioning. Although clinical trials with nutritional supplements are still limited and have inconsistent results, specific nutrients, as Omega-3, vitamin D and Group B vitamins can be useful as complementary strategies in the treatment of schizophrenia. It is hoped that the initiation of personalized medicine strategies, such as stratification and using a clinical staging approach, will make it possible to identify the subgroups of patients who can obtain maximum benefit from dietary and nutritional interventions (AU)
Asunto(s)
Humanos , Trastornos Psicóticos/dietoterapia , Esquizofrenia/dietoterapia , Dieta Saludable , Medicina de Precisión/tendencias , Ácidos Grasos Omega-3/uso terapéutico , Vitamina D/uso terapéutico , Complejo Vitamínico B/uso terapéutico , Microbioma Gastrointestinal/fisiologíaRESUMEN
OBJECTIVE: to evaluation of glutamate dehydrogenase (GDH) enzymatic activity in platelets of patients with endogenous psychoses. MATERIAL AND METHODS: Enzymatic cectivity of GDH evaluated in 69 patients with schizophrenia (n=48) or schizoaffective disorder (n=21) in comparison with control group (n=34) and elucidation of possible link between their platelet GDH activity and clinical psychopathological condition. RESULTS AND CONCLUSION: Generally, GDH activity in patients before antipsychotic treatment was significantly lower, than in control group. Significant differences were revealed in GDH activity before the treatment between subgroups of patients with first episode psychosis (FEP, n=34), chronic patients (n=35), and control group (n=34), wherein GDH activity correlated with PANSS in FEP patients before the treatment course. No links were found in patients with chronic schizophrenia. Besides, significant links between GDH activity determined before the treatment course and PANSS scores after the treatment were found in FEP patients: the higher were levels of platelet GDH activity in FEP patients, the lower were their PANSS scores after the treatment. CONCLUSION: Initial (baseline) levels of platelet GDH activity can have value for prognosis of antipsychotic pharmacotherapy efficacy in patients with FEP.
Asunto(s)
Plaquetas/enzimología , Glutamato Deshidrogenasa/metabolismo , Trastornos Psicóticos/enzimología , Antipsicóticos/uso terapéutico , Humanos , Pronóstico , Trastornos Psicóticos/sangre , Trastornos Psicóticos/dietoterapia , Esquizofrenia/sangre , Esquizofrenia/tratamiento farmacológico , Esquizofrenia/enzimologíaRESUMEN
AIM: It has been found that long-chain omega-3 polyunsaturated fatty acids (PUFAs) reduce the risk of progression to first episode of psychosis (FEP) and may offer a safe and efficacious strategy for selective and indicated prevention in young people with ultra-high-risk (UHR) states. An opportunity for exploring the trajectory of FEP and for investigating the efficacy of preventive treatments exists in 22q11.2 deletion syndrome (22q11DS), which has a 30% psychotic transition rate. The fact that 22q11DS patients are more homogeneous than other UHR groups and are characterized by high level of negative symptoms provides a strong rationale for the use of PUFAs. The principal aim of the present trial is to investigate the effects of PUFAs in individuals with 22q11DS who are at UHR for developing FEP. METHODS: A prospective, randomized, double-blind, placebo-controlled, single-centre study design will be used. Eighty individuals aged 12-26 will be randomly assigned to two treatment conditions. RESULTS: The experimental group will receive PUFAs. The placebo group will receive paraffin oil. Standard clinical assessments and neuropsychological tests will be performed at baseline and at 8-, 12-, 26- and 52-week follow-up. Blood samples will be collected at baseline and after 12 weeks. This study is registered as an International Standard RCT, number 02070211. The corresponding author is supported by a NARSAD Young Investigator Award. CONCLUSIONS: This is the protocol of a planned study that aims to test the efficacy of PUFAs in the prodromal phase of FEP, in a specific syndrome where there is strong evidence that a high genetic load is involved in the disorder.
Asunto(s)
Protocolos Clínicos , Síndrome de DiGeorge/dietoterapia , Ácidos Grasos Omega-3/uso terapéutico , Predisposición Genética a la Enfermedad/prevención & control , Trastornos Psicóticos/dietoterapia , Trastornos Psicóticos/prevención & control , Adolescente , Adulto , Niño , Síndrome de DiGeorge/complicaciones , Método Doble Ciego , Femenino , Predisposición Genética a la Enfermedad/genética , Humanos , Masculino , Síntomas Prodrómicos , Adulto JovenRESUMEN
Non-celiac gluten sensitivity (NCGS) is a syndrome diagnosed in patients with symptoms that respond to removal of gluten from the diet, after celiac disease and wheat allergy have been excluded. NCGS has been related to neuro-psychiatric disorders, such as autism, schizophrenia and depression. A singular report of NCGS presenting with hallucinations has been described in an adult patient. We report a pediatric case of a psychotic disorder clearly related to NCGS and investigate the causes by a review of literature. The pathogenesis of neuro-psychiatric manifestations of NCGS is unclear. It has been hypothesized that: (a) a "leaky gut" allows some gluten peptides to cross the intestinal membrane and the blood brain barrier, affecting the endogenous opiate system and neurotransmission; or (b) gluten peptides may set up an innate immune response in the brain similar to that described in the gut mucosa, causing exposure from neuronal cells of a transglutaminase primarily expressed in the brain. The present case-report confirms that psychosis may be a manifestation of NCGS, and may also involve children; the diagnosis is difficult with many cases remaining undiagnosed. Well-designed prospective studies are needed to establish the real role of gluten as a triggering factor in neuro-psychiatric disorders.
Asunto(s)
Dieta Sin Gluten , Glútenes/efectos adversos , Trastornos Psicóticos/dietoterapia , Trastornos Psicóticos/etiología , Adolescente , Femenino , Hipersensibilidad a los Alimentos , Humanos , Inmunoglobulina G/sangre , Complejo de Antígeno L1 de Leucocito/sangreRESUMEN
BACKGROUND: Evidence has been accumulating that it may be possible to achieve prevention in psychotic disorders. The aim of the Prevention Of Psychosis (POP) study is to reduce the annual incidence of psychotic disorders in a catchment area population through detection and intervention in the prodromal phase of disorder. Prodromal patients will be recruited through information campaigns modelled on the Scandinavian early Treatment and Intervention in Psychosis (TIPS) study and assessed by low-threshold detection teams. METHODS/DESIGN: The study will use a parallel control design comparing the incidence of first episode psychotic disorders between two Norwegian catchment areas with prodromal detection and treatment (Stavanger and Fonna) with two catchment areas without a prodromal intervention program (Bergen and Østfold). The primary aim of the current study is to test the effect of a Prodromal Detection and Treatment program at the health care systems level. The study will investigate: 1) If the combination of information campaigns and detection teams modelled will help in identifying individuals (age 13-65, fulfilling study inclusion criteria) at high risk of developing psychosis early, and 2) If a graded, multi-modal treatment program will reduce rates of conversion compared to the rates seen in follow-along assessments. DISCUSSION: Positive results could potentially revolutionize therapy by treating risk earlier rather than disorder later and could open a new era of early detection and intervention in psychosis. Negative results will suggest that the potential for psychosis is determined early in life and that research should focus more on genetically linked neurodevelopmental processes. If we can identify people about to become psychotic with high accuracy, we can track them to understand more about how psychosis unfolds. Appropriate intervention at this stage could also prevent or delay the onset of psychosis and/or subsequent deterioration, i.e., social and instrumental disability, suicide, aggressive behavior, affective- and cognitive deficits. TRIAL REGISTRATION: Current Controlled Trials ISRCTN20328848 . Registered 02 November 2014.
Asunto(s)
Ácidos Grasos Omega-3/uso terapéutico , Prevención Primaria/métodos , Síntomas Prodrómicos , Psicoterapia , Trastornos Psicóticos/dietoterapia , Trastornos Psicóticos/prevención & control , Trastornos Psicóticos/terapia , Adolescente , Adulto , Anciano , Encéfalo/fisiología , Protocolos Clínicos , Terapia Combinada , Diagnóstico Precoz , Femenino , Neuroimagen Funcional , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Trastornos Psicóticos/fisiopatología , Factores de Riesgo , Factores de Tiempo , Adulto JovenRESUMEN
Individual dietetic consultations were trialled in a community-based first-episode psychosis program. Participants received eight individualised dietetic consultations, plus weekly shopping tours and cooking groups. The outcome measure was waist circumference (WC). In total, 30 patients commenced the program. An intention-to-treat analysis revealed, a statistically significant reduction in WC (mean=2.1±5.4 cm, t=2.1, df=29, p=0.04). Similar results were found for the 14 participants who attended all eight sessions (mean WC reduction=2.9±4.7 cm, t=2.3, df=13, p=0.04). Dietetic consultations were feasible and effective in reducing WC, and could enhance programs to reduce cardiometabolic risk in youth with psychosis using lifestyle interventions.